Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Talk evidence covid-19 update - remdesivir redux, the overwhelming volume of research

Talk evidence covid-19 update - remdesivir redux, the overwhelming volume of research

FromTalk Evidence


Talk evidence covid-19 update - remdesivir redux, the overwhelming volume of research

FromTalk Evidence

ratings:
Length:
31 minutes
Released:
Jun 3, 2020
Format:
Podcast episode

Description

That remdesivir study has finally been published - what does it say and is it as independant as claimed. Also, as the world's focus turned to covid, so have researchers - and they've produced over 15000 papers. How can we sift through the flood of research and know what's any good?

(2.30) Helen Macdonald talks to Elizabeth Loder about the volume of research we're seeing, and why journals and peer reviewers are struggling to check it all.

(8.15) The study on remdesivir has been published - the trial was stopped early, and the primary outcome switched - we talk about how that increases uncertainty over the results, and could actually delay the treatment.

(26.50) We hear from a couple fo readers who wanted to correct us about averages, means, medians.

Reading list:
The US NIH AID study on remdesivir, published 22nd May in the New England Journal of Medicine

Research - preliminary report https://www.nejm.org/doi/full/10.1056/NEJMoa2007764
NEJM - looking at the dose duration https://www.nejm.org/doi/full/10.1056/NEJMoa2015301
Editorial - an important first step https://www.nejm.org/doi/full/10.1056/NEJMe2018715
Released:
Jun 3, 2020
Format:
Podcast episode

Titles in the series (71)

The podcast for evidence based medicine - where research, guidance and practice are debated and demystified